Sca-1 / c-kit receptor expression and apoptosis pattern in ENU induced MDS mice

Journal of Stem Cells

Volumn 4, Issue 4, 2009, Pages 229-241

  Das, Madhurima ^a   Chatterjee, Sumanta ^a   Basak, Pratima ^a   Das, Prosun ^a   Pereira, Jacintha Archana ^a   Dutta, Ranjan Kumar ^a   Chaklader, Malay ^a   Chaudhuri, Samaresh ^a   Law, Sujata ^a  

^a CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; CELL SURFACE RECEPTOR; ETHYLNITROSOUREA; MARKER; BIOLOGICAL MARKER; LY ANTIGEN; LY6A PROTEIN, MOUSE; MEMBRANE PROTEIN; NITROSOUREA DERIVATIVE; STEM CELL FACTOR RECEPTOR;

APLASIA; APOPTOSIS; ARTICLE; BACK; BASOPHIL; BLOOD CELL; BONE MARROW CELL; BONE MARROW DISEASE; CELL DIFFERENTIATION; CELL SURFACE; CONTROLLED STUDY; CYTOARCHITECTURE; DISEASE MODEL; EOSINOPHIL; ERYTHROBLAST; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; LEUKEMIA; LYMPHOCYTE; MALE; MONOCYTE; MOUSE; MUTATION; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; NONHUMAN; ONCOGENE C KIT; PRELEUKEMIA; PROGENY; PROTEIN EXPRESSION; RETICULOCYTE; TRANSGENIC MOUSE; ANIMAL; CHEMICALLY INDUCED; CYTOLOGY; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; STEM CELL; TOXICITY;

ANIMALS; ANTIGENS, LY; APOPTOSIS; BIOLOGICAL MARKERS; BONE MARROW CELLS; FLOW CYTOMETRY; HUMANS; MEMBRANE PROTEINS; MICE; MYELODYSPLASTIC SYNDROMES; NITROSOUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS C-KIT; STEM CELLS;

ANIMALIA; MURINAE; MUS; MUS MUSCULUS;

EID: 77956672547     PISSN: 15568539     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Zon, LI. Developmental Biology of Hematopoiesis. Blood, 1995, 86 (8), 2876-2891.
2. Mikkola, HKA ; Orkin, SH. The journey of developing hematopoietic stem cells. Development, 2006, 133, 3733-3744.
3. Munker, R; Hiller, E and Glass, J; Paquette, R. Basic biology of haemopoiesis. In: Munker R, Hiller E, Glass J, Phillipkoeffler H. Second edition. Modern Haematology Biology and Clinical management. Totowa New Jersey: Humana Press. 2006, 1, 1-18.
4. Huang, X; Cho, S; Spangrude, G J. Hematopoietic stem cells: generation and self-renewal. Cell Death and Differentiation, 2007, 14, 1851-1859.
5. Lucas, T; Krugluger, W; Samorapoompichit, P; Gamperl R; Beug, H; Förster, O; Nitulescu, GB. Self-renewal, maturation, and differentiation of the rat myelomonocytic hematopoietic stem cell. The FASEB Journal, 1999, 13, 263-272.
6. Nguyen D and Diamond L. Quantitative abnormalities in haematopoietic precursors. In: Arnold H. First Indian edn. Diagonistic Hematology A Pattern Approach. New Delhi. Jaypee Brothers Medical Publishers (P) Ltd; 2006, 288-295.
7. Stein, SR; Goodman, S. Anemias of bone marrow failure. Hospital physician, 2005, 41(2), 19-26.
8. D'Andrea, AD; Dahl, N; Guinan, EC; Shimamura, A. Marrow Failure. Hematology, 2002, 58-72.
9. Young NS. Acquired aplastic anemia. In:Young NS. Bone Marrow Failure Syndromes. Philadelphia, PA: W.B. Saunders Co., 2000, 1-46.
10. Khodke, K; Marwah, S; Buxi, G; Yadav, R; Chaturvedi, N. Bone Marrow Examination in Cases of Pancytopenia. Journal, Indian Academy of Clinical Medicine. 2001, 2(1) and (2). 55-59.
11. Varma, N; Varma, S; Marwaha, KR; Malhotra, P; Bansa, D; Malik, K; Kaur, S; Garewal G. Multiple constitutional aetiological factors in bone marrow failure syndrome (BMFS) patients from north India. Indian Journal of Medical Researh,.2006,124(1), 51-56.
12. Maciejewski, JP; Anderson, S; Katevas,P; Young, N.. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. British Journal of Haematology, 1994, 87, 227-234.
13. Risitano, AM; Maciejewski, JP; Selleri, C; Rotoli, B. Function and Malfunction of Hematopoietic Stem Cells in Primary Bone Marrow Failure Syndromes. Current Stem Cell Research and Therapy, 2007, 2, 39-52.
14. Boultwood, J; Wainscoat, JS. Clonality in the Myelodysplastic Syndromes. International Journal of Hematology, 2001, 73(4), 411-415.
15. Cazzoala, M; Malcovati, L. Myelodysplastic syndromes - coping with ineffective haematopoiesis. New England Journal of Medicine, 2005, 352(6), 536-539.
16. Michiels JJ; Meulen, JVD; Brederoo, P. The natural history of trilinear myelodysplastic syndrome and erythroleukemia. Haematologica, 1997, 82,452-454.
17. Shetty, VT; Mundle SD; Raza, A. Pseudo Pelger-Huët anomaly in myelodysplastic syndrome: hyposegmented or apoptotic neutrophil? Blood, 2001, 98 (4), 1273-1275.
18. Kuriyama, K; Tomonaga, M; Matsuo, T; Ginnai, I; Ichimaru, M. Diagnostic significance of detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelodysplastic syndrome. British Journal of Haematology, 1986, 63, 665-669.
19. Wen, JQ; Feng, HL; Wang, XQ; Pang, JP. Hemogram and bone marrow morphology in children with chronic aplastic anemia and myelodysplastic syndrome. World Journal of Pediatrics, 2008, 4 (1), 36-40.
20. Vardiman, JW. Hematological concept and controversies in the diagnosis and classification of Myelodysplastic syndrome. Hematology, 2006, 1, 199-204.
21. Nimer, SD. Myelodysplastic syndromes. Blood, 2008, 111(10). 4841-4851.
22. Jacobs, A. Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications. Journal Clinical Pathology. 1985, 38,1201-1217.
23. Nimer, SD. MDS: A Stem Cell Disorder - but What Exactly Is Wrong with the Primitive Hematopoietic Cells in This Disease? Hematology, 2008, 43-51.
24. Matsushima, T; Handa, H; Yokohama, A; Nagasaki, J; Koiso, H; Kin, Y; Tanaka, Y; Sakura, T; Tsukamoto, N; Karasawa, M; Itoh, K; Hirabayashi, H; Sawamura, M; Shinonome, S; Shimano, S; Miyawaki, S; Nojima, Y; Murakami, H. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood, 2003, 101(9), 3386-3390.
25. Albitar,M; Manshouri, T; Shen, Yu; Liu, D; Beran, M; Kantarjian, MH; Rogers, A; Jilani, I; Lin WC; Pierce, S; Freireich, JE; Estey, H. Myelodysplastic syndrome is not merely "preleukemia". Blood, 2002, 100(3).
26. Bagby, GC; Meyers, G. Bone Marrow Failure as a Risk Factor for Clonal Evolution: Prospects for Leukemia Prevention. Hematology, 2007, 1, 40-46.
27. JRP, Klener; Andera, L; Klener, P; Necas, E; Zivney, J. Cell Death Signaling Pathways in the Pathogenesis and Therapy of Haematologic Malignancies: Overview of Therapeutic Approaches. Folia Biologica (Praha). 2006, 52,119-136.
28. Liesveld, JL; Jordan, CT. and Phillips, JL, II. The hematopoietic stem cell in meylodysplasia. Stem cell, 2004, 22, 590-599.
29. Dar, S; Mundle, S; Andric, T; Qawi, H; Shetty, V; Reza, S. et al. Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis. European Journal of Haematololgy, 1999, 62, 90-4.
30. Parker, JE; Fishlock, KL; Mijovic, A; Czepulkowski, B; Pagliuca, A; Mufti, GJ. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2- related proteins. British Journal Haematology, 1998, 103, 1075 82.
31. Parker, JE; Mufti, GJ; Rasool, F; Mijovic, A; Devereux, S; Pagliuca, A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood, 2000, 96,3932-3938.
32. Vardiman, JW. Hematopathological Concepts and Controversies in the Diagnosis and Classification of Myelodysplastic Syndromes. American Society of Cell Biology, 199-204.
33. Bennett, JM; Orazi, A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica, 2009, 94(2), 264-268.
34. Elghetany, MT.Surface marker abnormalities in myelodysplastic syndromes. Haematologica, 1998; 83:1104-1115.
35. Zonghong S, Zhang hong, Guibin C, Wang-Li, Yizhi Z, Li L, Juan S. Expression and function of c-kit receptor in bone marrow mononuclear cells of patients with myelodysplastic syndromes. Chinese Medical Journal, 2001, 114(5), 481-485.
36. Chui,CH; Leung, PHM; Lau, FY; Wan, TSK; Chan, LC; Cheng, G. Lack of structural rearrangement in c-kit and stem cell factor genes in Hong Kong Chinese patients with myelodysplastic syndromes or acute myeloid leukaemia. Honkong Medical Journal, 1998, 4 (1), 27-29.
37. Chen J. Animal Models for Acquired Bone Marrow Failure Syndromes. Clinical Medicine and Research. 2005, 3 (2),102-108.
38. Noveroske, JK; Weber, JS; Justice, MJ. The mutagenic action of N-ethyl-N-nitrosourea in the mouse. Mammalian Genome. 2000. 11,478-483.
39. Koestner, A; Swenberg, JA; Wechsler, W. Transplacental Production with Ethyinitrosourea of Neoplasms of the Nervous System in Sprague-Dawley Rats. American Journal of Pathology, 1971, 63,8.39-59.
40. Claij, N; Wal, AVD; Dekker, M; Jansen, L; Riele, H. DNA mismatch repair deficiency stimulates N-Ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis. Cancer Research, 2003,63,2062-2066.
41. Chana,ER; Lavendera,H; Li, G; Haviernik, P; Bunting, KD; Adams, MD. An ENU-induced recessive mutation in Mpl leads to thrombocytopenia with overdominance. Experimental hematology, 2009. 37 (2), 276-284.
42. Tian, M; Campagna,DR; Woodward, LS; Justice, MJ; Fleming, MD. hem6 : an ENU-induced recessive hypochromic microcytic anemia mutation in the mouse. Blood, 2008, 112(10), 4308-4313.
43. Joslin, JM; Fernald, AA.; Tennant, TR. ; Davis, EM.; Kogan, SC; Anastasi, J; Crispino, JD; Beau, MML. Haploinsufficiency of EGR1, a candidate gene in the del (5q), leads to the development of myeloid disorders. The American Society of Hematology, 2007, 110(2), 719-726.
44. Vesselinovitch, SD; Rao, KVN; Mihailovich, N; Rice, JM;Lombard, LS. Development of Broad Spectrum of Tumors by Ethylnitrosourea in Mice and the Modifying Role of Age, Sex, and Strain. Cancer Research, 1974, 34,2530-2538.
45. Justice, M J; Carpenter, DA; Favor, J; Klaus, AN; Angelis, MH de; Soewarto, D; Moser, A; Cordes, S; Miller, D ; Chapman, V; Weber, J S; Rinchik, E M; Hunsicker, PR; Russell, WL; Bode ,VC. . Effects of ENU dosage on mouse strains. Mammalian Genome. 2000, 11,484-488.
46. Feng, J; Wang, H; Morse, HC III. Functional Deficiency in IL-7 Caused by an N-Ethyl-N-nitrosourea-Induced Point Mutation. Genetics, 2007, 175, 545-551.
47. Justice, M. J., Noveroske, J. K.; Weber, J. S.; Zheng, B. and Bradley,A. Mouse ENU mutagenesis. Human Molecular Genetics, 1999,8,1955-1963.
48. Rinchik, EM; and Carpenter, DA. N-Ethyl-N-nitrosourea-induced prenatally lethal mutations define at least two complementation groups within the embryonic ectoderm development (eed) locus in mouse chromosome7. Mammalian Genome, 1993, 4, 349-353.
49. Choi, CW; Chung,YJ; Slape, C; Aplan, PD. Impaired differentiation and apoptosis of hematopoietic precursors in a mouse model of myelodysplastic syndrome. Haematologica. 2008,93(9), 1394-1397.
50. Buonamici, S; Li, D; Chi, Y; Zhao, R; Wang, X; Brace, L; Hongyu, Ni; Saunthararajah, Y; Nucifora, G. EVI1 induces myelodysplastic syndrome in mice. Journal Clinical Investigation, 2004,114,713-719.
51. Thanopoulou, E; Cashman, J; Kakagianne, T; Eaves, A; Zoumbos, N; Eaves, C. Engraftment of NOD/SCID-β2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood, 2004, 103(11), 4285-4293.
52. Law, S; Basu,K; Banerjee, S; Begum, B; Das,PS; Chaudhuri, S. Isolation and ex-vivo expansion of stem cells: physiological manipulation for cytotherapy. Indian journal of Physiology and Allied Science, 2001, 55(3), 114-122.
53. Law, S; Maiti, D; Palit, A; Majumder, D; Basu, K; Chaudhuri,S; Chaudhuri, S. Facilitation of functional compartmentalization of bone marrow cells in leukemic mice by biological response modifiers: an immunotherapeutic approach. Immunology Letter, 2001, 76 (3), 145-152.
54. Law, S; Maiti, D; Palit, A; Chaudhuri, S. Role of biomodulators and involvement of protein tyrosine kinase on stem cell migration in normal and leukaemic mice. Immunology Letter, 2003, 86 (3), 287-290.
55. Law, S; Begum,B; Chaudhuri, S. Pluripotent Bone Marrow Cells in Leukemic Mice Elicit Enhanced Immune Reactivity Following Sheep Erythrocyte Administration in-vivo. A Possible S-LFA3 Interactive Immunotherapy. Journal of Experimental Clinical Cancer Research, 2003,22(2), 213-221.
56. Matsuo, T; Kuriyama, K; Miyazaki, Y; Yoshida, S; Tomonaga, M; Emi, N; Kobayashi, T; Miyawaki, S; Matsushima, T; Shinagawa, K; Honda S; Ohno, R. The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. Leukemia, 2003, 17, 1538-1543.
57. Hu, ZB; Ma, W; Uphoff, CC; Metge, K; Gignac, SM; Drexler, HG. Myeloperoxidase: expression and modulation in a large panel of human Leukemia - Lymphoma cell lines. Blood, 1993, 82, 1599-1607.
58. Suzuki, H; Asano, H; Ohashi, H, Kinoshita, T; Murate, T; Saito, H; Hotta, T. Clonality analysis of refractory anemia with ring sideroblasts: simultaneous study of clonality and cytochemistry of bone marrow progenitors. Leukemia, 1999, 13, 130-134.
59. Cazzola, M. Ring sideroblasts and myelodysplastic syndromes. Journal of Clinical Pathology, 1983,36,1413-1414.
60. Cazzola,M; Barosi, G; . Berzuini, C; Dacco, M; Orlandi, E; Stefanelli, M; Ascari, E. Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes. British Journal of Haematology.1982, 50,55-62.
61. Rothstein G. Disordered Hematopoiesis and Myelodysplasia in the Elderly. JAGS 51 (Suppl), 2003, 51, 3, 22-26.
62. Ramos, F; Nunez, MF; Vilela, D S;Lopez, AF. What does apoptosis have to do with clinical features in myelodysplastic syndrome? Haematologica, 2002, 87, 381-391.
63. Shetty, V; Hussaini, S; Robinson, LTB; Allampallam, K; Mundle, S; Borok, R; Broderick, E; Mazzoran, L; Zorat, F; Raza, A. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood, 2000, 96, 1388-1392.
64. Celkan, T.; Apak, H.; Özkan, A; Aki, H; Tapyüreklý, M; Lebriz, Y; Ýnci, Y. A Case with Micromegakaryocytes.Turkish Journal of Haematol. 2001,18(3), 203-206.
65. Yuan, Y; Zhou, L; Miyamoto, T; Iwasaki, H; Harakawa, N; Hetherington, CJ; Burel, SA; Lagasse, E; Weissman, IL; Akashi, K; Zhang, DE. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. PNAS, 2001, 98, 8 10398-10403.
66. Cunningham, I; MacCallum, SJ; Nicholls, MD; et al. The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. British Journal of Haematology, 1995, 90,602-606.
67. Jain, NC; Kono, CS; Madewell, BR. Cytochemical studies of normal feline blood and bone marrow cells. Annals of Hematology, 1989, 58(4), 195-199.
68. Eivaziziaei, J; Dastgiri, S. Role of myeloperoxidase index in differentiation of megaloblastic and aplastic anemia. Indian Journal of Medical Science, 2004, 58 (8), 345-348.
69. Klebanoff, SJ. Myeloperoxidase: friend and foe. Journal of Leukocyte Biology, 2005.77,1-28.
70. Schmalzl, F; Konwalinka, G; Michlmayr, G; Abbrederis,K; Braunsteiner, H. Detection of cytochemical and Morphological anomalies in 'Preleukemia'. Acta Haematologica, 1978, 59,1-18.
71. Steensma, DP; Tefferi, A. JAK2 V617F and ringed sideroblasts: not necessarily RARS-T. Blood, 2008, 111(3), 1747-1748.
72. Chodirker, L; Wells, RA. Iron overload in myelodysplastic syndrome. Expert Review of Hematology, 2009, 2(3), 215-218.
73. Virginia, CB. Stem Cell Factor and Hematopoiesis. Blood, 1997, 90(4), 1345-1364.
74. Okada, S; Nakauchi, H; Nagayoshi, K; Nishikawa, S; Miura, Y; Suda, T. In Vivo and in vitro stem cell function of C-kit and Sca 1 positive murine hematopoietic stem cells. Blood, 1992, 80, 3044-3050.
75. Gersuk , GM; Beckham, C; Loken, MR; Kiener, P; Anderson, JE; Farraand, A; Troutt, AB; Ledbetter, JA; Deeg, HJ. A role for tumor necrosis factor-α, Fas and Fas -ligand in marrow failure associated with myelodysplastic syndrome. British Journal of Haematology, 1998, 103, 176-188.
76. Smith, MA; Smith, JG. The occurrence subtype and significance of hematopoietic inhibitory T cells (HIT) cells in myelodysplasia: an in vitro study. Leukemia Research, 1991, 15, 597-601.